All In Biotech

Free tool

FAERS Monitor: Qamzova

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217593 or its brand name (Qamzova, Meloxicam). Reports on generic versions are filed under their own applications.

Reports

58,670

Serious

33,720

57% of reports

Hospitalization

14,036

Death reported

3,800

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective6,182
  • pain4,886
  • fatigue4,833
  • arthralgia4,413
  • nausea4,028
  • headache3,527
  • diarrhoea3,424
  • dyspnoea2,829
  • dizziness2,784
  • off label use2,751
  • pain in extremity2,683
  • malaise2,612
  • vomiting2,375
  • rheumatoid arthritis2,346
  • rash2,341

Reports by year received

View as table
YearReports
2004211
2005311
2006189
2007335
2008525
2009649
2010836
20111,126
20121,711
20131,806
20142,246
20153,478
20164,710
20174,207
20184,905
20195,286
20205,035
20213,923
20223,747
20233,558
20243,586
20253,661
20262,629

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,995,489 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
rheumatoid arthritisSignal2,3467.57.213,104
arthralgiaSignal4,4133.83.79,332
pain in extremitySignal2,6833.33.24,284
painSignal4,8862.92.86,066
fatigueSignal4,8332.22.23,395
malaiseSignal2,6122.12.11,613
headacheSignal3,5272.02.01,868
dizzinessSignal2,7842.01.91,431
rash2,3411.91.91,065
diarrhoea3,4241.91.81,513
nausea4,0281.81.81,563
vomiting2,3751.81.7884
dyspnoea2,8291.81.71,019
drug ineffective6,1821.71.61,826
off label use2,7511.11.141

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.